Physician profile
Michael Teiger
NPI 1245343672
$7,065.06
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $740 · 2021: $1,849 · 2022: $2,538 · 2023: $80.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $80.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $80.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,803.90 | 2019-2022 | |
| Glaxosmithkline, LLC. | $2,224.24 | 2019-2022 | |
| Mylan Specialty L.P. | $483.68 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.86 | 2019-2022 | |
| Genzyme Corporation | $304.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $272.70 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $136.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $126.58 | 2019-2022 | |
| Covis Pharma Gmbh | $91.50 | 2022 | |
| Amgen INC. | $62.68 | 2022 | |
| Genentech USA, INC. | $47.17 | 2022 | |
| Grifols USA, LLC | $42.51 | 2019 | |
| Circassia INC. | $42.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.90 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $15.47 | 2022 | |
| Electromed, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Teiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.